Bevacizumab是一种合成的抗血管内皮生长因子抗体片段,通过前房或玻璃体腔注射Bevacizumab,能促进虹膜和前房角新生血管的消退,显著降低眼压,可单独或联合手术治疗新生血管性青光眼;同时在青光眼滤过性手术中或在失败的滤过泡中应用,能显著提高手术的成功率,为青光眼的治疗开辟了新的途径,本文综述了这方面的进展。 Bevacizumab is a synthetic anti-vascular endothelial growth factor antibody fragment through the anterior chamber or intravitreal injection of Bevacizumab, can promote iris and anterior chamber angle neovascularization subside, significantly reduce intraocular pressure, either alone or in combination with surgical treatment of neovascular glaucoma ; At the same time in glaucoma filtration surgery or in the failure of filtration bleb application, can significantly improve the success rate of surgery, opened up a new way for the treatment of glaucoma, this article reviews the progress.